{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:00:21Z","timestamp":1790874021385,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81470353"],"award-info":[{"award-number":["Grant No. 81470353"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870155"],"award-info":[{"award-number":["81870155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700195"],"award-info":[{"award-number":["81700195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Plasmablastic lymphoma (PBL) is a rare but aggressive B-cell lymphoma subtype with poor prognosis. Knowledge about the etiology, clinicopathologic and molecular features, and outcomes of PBL is limited. This study aimed to examine the clinicopathologic characteristics, therapeutic approaches, and clinical outcomes of PBL patients in a Chinese population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 102 PBL patients were recruited from three cancer centers. The pathologic features and clinical outcomes of 56 patients with available treatment details and follow-up data were reviewed and analyzed. RNA sequencing was performed in 6 PBL and 11 diffuse large B-cell lymphoma (DLBCL) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Most patients in our cohort were male (<jats:italic>n<\/jats:italic>\u2009=\u200936, 64.3%), and 35 patients presented with Ann Arbor stage I\/II disease at diagnosis. All these patients showed negative findings for human immunodeficiency virus, and the vast majority of patients in our cohort were immunocompetent. Lymph nodes (<jats:italic>n<\/jats:italic>\u2009=\u200913, 23.2%) and gastrointestinal tract (<jats:italic>n<\/jats:italic>\u2009=\u200910, 17.9%) were the most commonly involved site at presentation. Post-treatment complete remission (CR) was the only prognostic factor affecting overall survival (OS) and progression-free survival (PFS) in the multivariate analysis. RNA-seq demonstrated that B-cell receptor (BCR), T-cell receptor (TCR), P53, calcium signaling, and Wnt signaling pathways were significantly downregulated in PBLs compared with GCB (or non-GCB) DLBCLs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this multicenter study in the Chinese population, PBL mainly occurred in immunocompetent individuals and most patients present with early-stage disease at diagnosis. Post-treatment CR was an important prognostic factor affecting OS and PFS. RNA-seq showed that the B-cell receptor (BCR), P53, calcium signaling, cell adhesion molecules, and Wnt signaling pathways significantly differed between PBL and GCB (or non-GCB) DLBCL, which provided theoretical basis for its pathogenesis and future treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02683-9","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T11:04:16Z","timestamp":1671102256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China"],"prefix":"10.1186","volume":"20","author":[{"given":"Di","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Chun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Peng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Juan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"issue":"4","key":"2683_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mdw684","volume":"28","author":"E Tchernonog","year":"2017","unstructured":"Tchernonog E, Faurie P, Coppo P, Monjanel H, Bonnet A, Algarte Genin M, Mercier M, Dupuis J, Bijou F, Herbaux C, et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017;28(4):843\u20138.","journal-title":"Ann Oncol"},{"key":"2683_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","volume":"8","author":"S Loghavi","year":"2015","unstructured":"Loghavi S, Alayed K, Aladily TN, Zuo Z, Ng SB, Tang G, Hu S, Yin CC, Miranda RN, Medeiros LJ, et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015;8:65.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2683_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","volume":"38","author":"J Morscio","year":"2014","unstructured":"Morscio J, Dierickx D, Nijs J, Verhoef G, Bittoun E, Vanoeteren X, Wlodarska I, Sagaert X, Tousseyn T. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38(7):875\u201386.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"2683_CR4","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","volume":"34","author":"A Valera","year":"2010","unstructured":"Valera A, Balague O, Colomo L, Martinez A, Delabie J, Taddesse-Heath L, Jaffe ES, Campo E. IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686\u201394.","journal-title":"Am J Surg Pathol"},{"key":"2683_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1756-8722-2-47","volume":"2","author":"CC Chang","year":"2009","unstructured":"Chang CC, Zhou X, Taylor JJ, Huang WT, Ren X, Monzon F, Feng Y, Rao PH, Lu XY, Fabio F, et al. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009;2:47.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2683_CR6","doi-asserted-by":"publisher","first-page":"1995166","DOI":"10.1080\/2162402X.2021.1995166","volume":"10","author":"JW Li","year":"2021","unstructured":"Li JW, Shi D, Wan XC, Hu J, Su YF, Zeng YP, Hu ZJ, Yu BH, Zhang QL, Wei P, et al. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma. Oncoimmunol. 2021;10(1):1995166.","journal-title":"Oncoimmunol"},{"issue":"4","key":"2683_CR7","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3892\/or.2015.3808","volume":"33","author":"M Liu","year":"2015","unstructured":"Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, Dong L. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases. Oncol Rep. 2015;33(4):1615\u201320.","journal-title":"Oncol Rep"},{"issue":"10","key":"2683_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/ajh.21250","volume":"83","author":"J Castillo","year":"2008","unstructured":"Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83(10):804\u20139.","journal-title":"Am J Hematol"},{"issue":"2","key":"2683_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/path.5108","volume":"246","author":"Z Liu","year":"2018","unstructured":"Liu Z, Cai Y, Yang Y, Li A, Bi R, Wang L, Shen X, Wang W, Jia Y, Yu B, et al. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma. J Pathol. 2018;246(2):141\u201353.","journal-title":"J Pathol"},{"issue":"3","key":"2683_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/leu.2017.299","volume":"32","author":"YJ Jia","year":"2018","unstructured":"Jia YJ, Liu ZB, Wang WG, Sun CB, Wei P, Yang YL, You MJ, Yu BH, Li XQ, Zhou XY. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma. Leukemia. 2018;32(3):703\u201311.","journal-title":"Leukemia"},{"issue":"15","key":"2683_CR11","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","volume":"125","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323\u201330.","journal-title":"Blood"},{"issue":"9","key":"2683_CR12","doi-asserted-by":"publisher","first-page":"e5981","DOI":"10.1097\/MD.0000000000005981","volume":"96","author":"X Han","year":"2017","unstructured":"Han X, Duan M, Hu L, Zhou D, Zhang W. Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis. Med (Baltimore). 2017;96(9):e5981.","journal-title":"Med (Baltimore)"},{"issue":"9","key":"2683_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","volume":"14","author":"SM Horwitz","year":"2016","unstructured":"Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, et al. NCCN Guidelines Insights: Non-Hodgkin\u2019s Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016;14(9):1067\u201379.","journal-title":"J Natl Compr Canc Netw"},{"issue":"21","key":"2683_CR14","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1002\/cncr.27551","volume":"118","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Furman M, Beltran BE, Bibas M, Bower M, Chen W, Diez-Martin JL, Liu JJ, Miranda RN, Montoto S, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118(21):5270\u20137.","journal-title":"Cancer"},{"issue":"3","key":"2683_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","volume":"15","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15(3):293\u20139.","journal-title":"Oncologist"},{"issue":"7277","key":"2683_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88\u201392.","journal-title":"Nature"},{"issue":"1","key":"2683_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/imr.12792","volume":"291","author":"RM Young","year":"2019","unstructured":"Young RM, Phelan JD, Wilson WH, Staudt LM. Pathogenic B-cell receptor signaling in lymphoid malignancies: new insights to improve treatment. Immunol Rev. 2019;291(1):190\u2013213.","journal-title":"Immunol Rev"},{"issue":"2","key":"2683_CR18","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 2019;6(2):e67\u201378.","journal-title":"Lancet Haematol"},{"issue":"13","key":"2683_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211\u201323.","journal-title":"N Engl J Med"},{"issue":"11","key":"2683_CR20","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/leu.2015.109","volume":"29","author":"J Chapman","year":"2015","unstructured":"Chapman J, Gentles AJ, Sujoy V, Vega F, Dumur CI, Blevins TL, Bernal-Mizrachi L, Mosunjac M, Pimentel A, Zhu D, et al. Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia. 2015;29(11):2270\u20133.","journal-title":"Leukemia"},{"issue":"1","key":"2683_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13046-022-02269-6","volume":"41","author":"B Klimovich","year":"2022","unstructured":"Klimovich B, Meyer L, Merle N, Neumann M, K\u00f6nig AM, Ananikidis N, Keber CU, Elmsh\u00e4user S, Timofeev O, Stiewe T. Partial p53 reactivation is sufficient to induce cancer regression. J Exp Clin Cancer Res. 2022;41(1):80.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2683_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41419-022-05021-2","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Li M, Zhang L, Sun F, Chen H, Xu Y, Lan Y, Zhang L, Lu S, Zhu J, et al. IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma. Cell Death Dis. 2022;13(6):572.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2683_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang G, Ren C, Li C, Wang Y, Chen B, Wen L, Jia M, Li K, Mok H, Cao L, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 2022;20(1):142.","journal-title":"BMC Med"},{"issue":"22","key":"2683_CR24","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2018889931","volume":"133","author":"M Pascual","year":"2019","unstructured":"Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino M-J, Panizo C, Hervas-Stubbs S, Alignani D, Sagardoy A, Martinez-Ferrandis JI, Bunting KL, et al. PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133(22):2401\u201312.","journal-title":"Blood"},{"issue":"5","key":"2683_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"},{"issue":"7360","key":"2683_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298\u2013303.","journal-title":"Nature"},{"issue":"14","key":"2683_CR27","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","volume":"129","author":"VA Gupta","year":"2017","unstructured":"Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood. 2017;129(14):1969\u201379.","journal-title":"Blood"},{"issue":"3","key":"2683_CR28","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1096\/fj.201901783RR","volume":"34","author":"M Taniguchi","year":"2020","unstructured":"Taniguchi M, Ueda Y, Matsushita M, Nagaya S, Hashizume C, Arai K, Kabayama K, Fukase K, Watanabe K, Wardhani LO, et al. Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAM-1 reduction. FASEB J. 2020;34(3):3838\u201354.","journal-title":"FASEB J"},{"key":"2683_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fonc.2018.00533","volume":"8","author":"A Slomp","year":"2018","unstructured":"Slomp A, Peperzak V. Role and regulation of pro-survival BCL-2 proteins in multiple myeloma. Front Oncol. 2018;8:533.","journal-title":"Front Oncol"},{"issue":"13","key":"2683_CR30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207\u201319.","journal-title":"N Engl J Med"},{"key":"2683_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.V128.22.4486.4486","volume":"128","author":"KR Kelly","year":"2016","unstructured":"Kelly KR, Siegel DS, Chanan-Khan AA, Somlo G, Heffner LT, Jagannath S, Zimmerman T, Munshi NC, Madan S, Mohrbacher A, et al. Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed \/ refractory multiple myeloma. Blood. 2016;128:22.","journal-title":"Blood"},{"key":"2683_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm11164928","volume":"11","author":"YK Ryu","year":"2022","unstructured":"Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE. Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma. J Clin Med. 2022;11:16.","journal-title":"J Clin Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02683-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T11:07:53Z","timestamp":1671102473000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02683-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2683"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02683-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"assertion":[{"value":"14 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was performed in accordance with the Declaration of Helsinki and approved by Ethics Institutional Review Board (IRB) of Fudan University Shanghai Cancer Center  (the approval number: 050432\u20134-2108), and informed consent was obtained from all participants included in the study in agreement with institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"483"}}